These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20493449)

  • 1. [What's new in 2009 in prostate cancer: highlights from ASTRO, EAU, ASCO and AUA meetings].
    Salomon L; Peyromaure M; Mongiat-Artus P; Roset F; Gachignard N; Bastide C; Richaud P; Beuzeboc P; Cornud F; Molinié V; Soulié M; Benchikh El Fegoun A;
    Prog Urol; 2010 Mar; 20 Suppl 1():S61-7. PubMed ID: 20493449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [What's new in 2008 in the field of basic and clinical research in prostate cancer?].
    Phé V; Rouprêt M; Salomon L; Soulié M
    Prog Urol; 2009 May; 19 Suppl 2():S29-42. PubMed ID: 19447327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
    Milecki P; Kwias Z; Martenka DJ
    Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Androgen deprivation therapy in locally advanced prostate cancer].
    Rossi D; Beuzeboc P; Staerman F; Timsit MO; Benchikh El Fegoun A
    Prog Urol; 2010 Mar; 20 Suppl 1():S68-71. PubMed ID: 20493450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prostate cancer: news in 2008].
    Salomon L; Descazeaud A
    Prog Urol; 2008 Sep; 18 Suppl 6():S116-24. PubMed ID: 18822261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [What's new in 2009 about urothelial tumors? Live from EAU, AUA and ASCO, ASCO-GU].
    Amsellem-Ouazana D; Theodore C; Irani J; Bernardini S; Bonnal JL; Chauvet B; Colombel M; Davin JL; Laurent G; Lebret T; Maidenberg M; Mazerolles C; Pfister C; Roupret M; Roy C; Rozet F; Saint F; Soulié M; Guillotreau J
    Prog Urol; 2010 Mar; 20 Suppl 1():S38-40. PubMed ID: 20493442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Practice guideline 'Prostate cancer: diagnosis and treatment'].
    de Reijke TM; Battermann JJ; van Moorselaar RJ; de Jong IJ; Visser AP; Burgers JS
    Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1771-5. PubMed ID: 18754308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innovative approaches to the hormonal treatment of advanced prostate cancer.
    Trachtenberg J
    Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
    Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
    Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA relapse prostate cancer: the importance of tailored therapy.
    Aranha O; Vaishampayan U
    Urol Oncol; 2004; 22(1):62-9. PubMed ID: 14969807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EAU guidelines on prostate cancer.
    Aus G; Abbou CC; Bolla M; Heidenreich A; Schmid HP; van Poppel H; Wolff J; Zattoni F;
    Eur Urol; 2005 Oct; 48(4):546-51. PubMed ID: 16046052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ
    Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developments in urologic oncology "OncoForum": The best of 2017.
    Gómez-Veiga F; Alcaraz-Asensio A; Burgos-Revilla J; Cózar-Olmo J
    Actas Urol Esp (Engl Ed); 2018 Oct; 42(8):488-498. PubMed ID: 29935800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan.
    Hachiya T; Akakura K; Saito S; Shinohara N; Sato K; Harada M; Kato T; Okada K
    BJU Int; 2005 Mar; 95(4):534-40. PubMed ID: 15705075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced prostate cancer: what's new in hormonal manipulation?
    Brewster SF; Gillatt DA
    Br J Hosp Med; 1993 May 19-Jun 1; 49(10):710-1, 714-5. PubMed ID: 7686805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG; Crawford ED; DeAntoni EP
    Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.